Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

(2012) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

(2012) Jin Soo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

(2012) Paulo M. Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

(2012) Hans-Joachim Schmoll et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

(2011) Eloisa Jantus-Lewintre et al.   LUNG CANCER

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2010) C. Pena et al.   CLINICAL CANCER RESEARCH

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

(2009) N Murukesh et al.   BRITISH JOURNAL OF CANCER

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer

(2009) E. O. Hanrahan et al.   CLINICAL CANCER RESEARCH

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

(2008) C. A. Heckman et al.   CANCER RESEARCH

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study

(2008) A. Dowlati et al.   CLINICAL CANCER RESEARCH

Anti-VEGF therapy: the search for clinical biomarkers

(2008) Raffaele Longo et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS